Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 13 (12), e0209352
eCollection

Clinical Characteristics and Outcomes of Primary Sclerosing Cholangitis and Ulcerative Colitis in Japanese Patients

Affiliations

Clinical Characteristics and Outcomes of Primary Sclerosing Cholangitis and Ulcerative Colitis in Japanese Patients

Junichiro Kumagai et al. PLoS One.

Abstract

Background: In Western countries, most patients with primary sclerosing cholangitis (PSC) have concurrent ulcerative colitis (UC). The number of patients with UC in East Asia has increased markedly over the past two decades. However, current clinical features of PSC and of PSC associated with UC (PSC-UC) have not yet been clarified in East Asia, particularly in Japan. We aimed to reveal the clinical courses and associations with UC in Japanese patients with PSC from the mutual viewpoint of PSC and UC.

Methods: We retrospectively retrieved medical records of patients with PSC (69) and UC (1242) who were diagnosed at Chiba University Hospital between June 1991 and August 2017.

Results: In the present cohort, 37 patients had PSC-UC; the cumulative risks of PSC in patients with UC and of UC in patients with PSC were 3.0% and 53.6%, respectively. We confirmed similar distinctive results by a Japanese nationwide survey, noting that younger patients with PSC had a notably high possibility of association with UC. From the viewpoint of the UC cohort, the occurrence of right-sided disease was significantly higher in patients with PSC-UC than in those with UC (16.2% vs. 4.2%, P = 0.003). Pancolitis was more commonly observed in PSC-UC, and proctits/left-sided colitis was less commonly found in patients with UC. The number of patients with young-onset PSC-UC may be increasing similar to an increase in patients with UC in Japan.

Conclusions: In our cohort, the comorbidity rate of PSC-UC was higher than that obtained in previous reports. The incidence of PSC-UC and UC may increase in the future in East Asia, particularly in Japan.

Conflict of interest statement

Potential competing interests: Tomoo Nakagawa received unrestricted research grant from AbbVie, Otsuka, EA pharma, Mochida, JIMRO, Asahikasei-Medical, and Nihonkayaku. Makoto Arai received unrestricted research grant from MSD, Daiichi-Sankyo, and Takeda. Naoya Kato received unrestricted research grant from AbbVie. The remaining authors disclose no conflicts. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Clinical courses of 69 patients with PSC focusing on age at onset and disease duration.
Fig 2
Fig 2. Progression from initial diagnosis to DS in 69 patients with PSC. DS, dominant stricture; PSC, primary sclerosing cholangitis.
Fig 3
Fig 3
Kaplan-Meier curves of survival (A), liver transplantation free survival (B), time to liver transplantation candidacy (C) from PSC diagnosis, and survival from UC diagnosis (D).
Fig 4
Fig 4
Correlations between date of birth and age at diagnosis in patients with UC (A) and PSC-UC (B).

Similar articles

See all similar articles

References

    1. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013;382: 1587–1599. 10.1016/S0140-6736(13)60096-3 - DOI - PubMed
    1. Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol 2015;110: 646–659. 10.1038/ajg.2015.112 - DOI - PubMed
    1. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and Management of primary sclerosing cholangitis. Hepatology 2010;51: 660–678. 10.1002/hep.23294 - DOI - PubMed
    1. Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology 2017;152: 1975–1984. 10.1053/j.gastro.2017.02.038 - DOI - PMC - PubMed
    1. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58: 2045–2055. 10.1002/hep.26565 - DOI - PubMed

Publication types

Grant support

Tomoo Nakagawa received unrestricted research grant from AbbVie, Otsuka, EA pharma, Mochida, JIMRO, Asahikasei-Medical, and Nihonkayaku. Makoto Arai received unrestricted research grant from MSD, Daiichi-Sankyo, and Takeda. Naoya Kato received unrestricted research grant from AbbVie. The remaining authors disclose no conflicts. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Feedback